



## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE

the specification of which (check one)

- [ ] is attached hereto.
- [X] was filed on 17 August 2000 as Serial No. PCT/EP00/08048 and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

## Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9919840.0	GREAT BRITAIN	20 August 1999	Yes
9920150.1	GREAT BRITAIN	25 AUGUST 1999	Yes
0019084.3	GREAT BRITAIN	3 AUGUST 2000	Yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

iling Date
•

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.



Serial No.

Filing Date

Status

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Post Office Address:

Address all correspondence and telephone calls to Dara Dinner, GlaxoSmithKline, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-5017.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor:	Nathalie Claude Marianne BAR	GES
Inventor's Signature:		Date: 24-11.02.
Residence: MAYE	NNE, CEDEX, FRANCE	FRX
Citizenship: FRENC	CH	
Post Office Address:	GlaxoSmithKline Corporate Intellectual Property - P.O. Box 1539 King of Prussia, Pennsylvania 19	
Full Name of Inventor: J	acky Andre Gustave MENTION	<del></del> .
Inventor's Signature:		Date:
Residence: LEOG	<u>NAN,</u> FRANCE	FRX
Citizenship: FRENC	СН	
	Full Name of Inventor:  Inventor's Signature:  Residence: MAYE  Citizenship: FRENC  Post Office Address:  Full Name of Inventor: J  Inventor's Signature:  Residence: LEOGN	Inventor's Signature:  Residence: MAYENNE, CEDEX, FRANCE  Citizenship: FRENCH  Post Office Address: GlaxoSmithKline

Corporate Intellectual Property - UW2220

King of Prussia, Pennsylvania 19406-0939

GlaxoSmithKline

P.O. Box 1539

Docket No.: P32396

## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE

the spe	ecification of whi	ch (chec	k one)		
[]	is attached here	eto.			
[X]	was filed on	17 Au	gust 2000	as Serial No. PCT/EP00/08048	
	and was amend	led on	(if appli	cable).	

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

## Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9919840.0	GREAT BRITAIN	20 August 1999	Yes
9920150.1	GREAT BRITAIN	25 AUGUST 1999	Yes
0019084.3	GREAT BRITAIN	<b>3 AUGUST 2000</b>	Yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

reprised trained time bate	Application Number	Filing Date	
----------------------------	--------------------	-------------	--

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status	

The first of the transfer that the second of the second of

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to Dara Dinner, GlaxoSmithKline, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-5017.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of In	ventor:	Nathalie Claude Marianne BARGES
Inventor's Signa	iture:	Date:
Residence:	MAYE	NNE, CEDEX, FRANCE
Citizenship:	FRENC	СН
Post Office Add	iress:	GlaxoSmithKline Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, Pennsylvania 19406-0939
Full Name of In Inventor's Signa Residence:	ature:	Date: 10 September 2002

Post Office Address: GlaxoSmithKline

**FRENCH** 

Citizenship:

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939